| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - APA: Bupropion and Hypoactive Sexual Desire Disorder By Lara Pullen Special to DG News CHICAGO, IL -- May 19, 2000 -- Bupropion sustained release (SR) may be an effective treatment for hypoactive sexual desire disorder (HSDD) in non-depressed women. At the 2000 Annual Meeting of the American Psychiatric Association, in Chicago, IL, R. Taylor Segraves, MD, and Kathleen B. Segraves, MD, both of Case Western Reserve University, Cleveland, OH, presented the results of a multicenter, single-blind study designed to test the safety and efficacy of bupropion SR. The study included a four-week placebo phase followed by an eight-week treatment phase. Non-depressed women (n=51) were at least 20 years of age with a diagnosis of HSDD for at least the preceding six months as defined in the Diagnostic and Statistical Manual (DSM)-IV. The following variables were assessed at each biweekly clinic visit (beginning at day 0): Investigator-Rated Sexual Desire and Sexual Functioning Assessments, Clinical Global Impressions Scale for Improvement of Illness (CGI-I), and Clinical Global Impressions Scale for Severity of Illness (CGI-S). Of the 51 women who continued into the treatment phase, 15 (29 percent) were considered to be responders, with response seen as early as two weeks after beginning treatment. In addition, bupropion SR was generally well-tolerated. Dr. Kathleen Segraves believes that further study is warranted and explained, "that we saw anything in that short amount of time is excellent." Related links: Bupropion.
|